References: Anticoagulation to prevent thromboembolic events in patients with atrial fibrillation and obesity

  • Martin KA, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost 2021. https://www.ncbi.nlm.nih.gov/pubmed/34259389
  • Mocini D, Di Fusco SA, Mocini E, Donini LM, Lavalle C, Di Lenarda A, et al. Direct Oral Anticoagulants in Patients with Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO). J Clin Med 2021;10(18). https://www.ncbi.nlm.nih.gov/pubmed/34575306
  • Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace 2021;23(10):1612-76. https://www.ncbi.nlm.nih.gov/pubmed/33895845